AstraZeneca Pharmaceuticals LP
NEWS
In July, the study was paused after another patient experienced neurological issues.
AstraZeneca paused its Phase III COVID-19 vaccine trial following a report of an “unexplained illness” in a patient involved in the study.
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
The U.S. government has financially backed the development of six different vaccine candidates aimed at the novel coronavirus. Although billions of dollars have been appropriated to the pandemic, at least four of those potential preventative treatments are predicted to fail in the clinic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 2, 2020.
The U.S. expansion will recruit up to 30,000 adults over the age of 18 years from a broad range of racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions.
AstraZeneca’s Farxiga (dapagliflozin) dramatically prolonged survival in patients with chronic kidney disease in a Phase III clinical trial.
JOBS
IN THE PRESS